专利检索 ap:"Sören Giese" 第 1 页

1.

发明授权
Fused cyclic modulators of nuclear hormone receptor function 有权
标题翻译：核激素受体功能的融合循环调节剂

公开(公告)号：US07001911B2

公开(公告)日：2006-02-21

申请号：US10322306

申请日：2002-12-18

申请人： Mark E. Salvati , James Aaron Balog , Weifang Shan , Sören Giese , Lalgudi S. Harikrishnan

发明人： Mark E. Salvati , James Aaron Balog , Weifang Shan , Sören Giese , Lalgudi S. Harikrishnan

IPC分类号： C07D471/08 , C07D471/18 , C07D487/08 , A61K31/439 , A61P35/00

CPC分类号： C07D487/08 , A61K31/00 , A61K31/407 , A61K31/655 , A61K31/675 , C07D487/14 , A61K2300/00

摘要： The invention pertains to fused cyclic compounds having the formula, wherein G is an optionally substituted aryl or heterocyclo, L is an optional linker, M is a bond, O, CR7R7′ or NR10, and M′ is a bond or NR10, with the proviso that at least one of M or M′ must be a bond; E is C═Z2, CR7CR7′, SO2, P═OR2, or P═OOR2; Z1 is O, S, NH, or NR6; Z2 is O, S, NH, or NR6; A1 is CR7 or N; A2 is CR7 or N; Y is J—J′—J″ where J is (CR7R7′)n and n=0-3, J′ is a bond or O, S, S═O, SO2, NH, NR6, C═O, OC═O, NR1C═O, CR7R7′, C═CR8R8′, R2P═O, OPOOR2, OPO2, OSO2, C═N, NHNH, NHNR6, NR6NH, N═N, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo or aryl or substituted aryl, and J″ is (CR7R7′)n and n=0-3; W is CR7R7′—CR7R7′, CR8═CR8′, CR7R7′—C═O, NR9—CR7R7′, N═CR8, N═N, NR9—NR9′, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, or aryl or substituted aryl; and O, R2, R6, R7, R7′, R8, R8′, R9, R9′, and R10 are as defined in the specification, to methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and to pharmaceutical compositions containing such compounds.

摘要翻译： 本发明涉及具有甲醛的稠合环状化合物

2.

发明授权
Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function 有权

公开(公告)号：US07141578B2

公开(公告)日：2006-11-28

申请号：US10974049

申请日：2004-10-25

申请人： Mark E. Salvati , James Aaron Balog , Dacia A. Pickering , Sören Giese , Aberra Fura , Wenying Li , Ramesh N. Patel , Ronald L. Hanson , Toomas Mitt , Jacques Y. Roberge , James R. Corte , Steven H. Spergel , Richard A. Rampulla , Raj N. Misra , Hai-Yun Xiao

发明人： Mark E. Salvati , James Aaron Balog , Dacia A. Pickering , Sören Giese , Aberra Fura , Wenying Li , Ramesh N. Patel , Ronald L. Hanson , Toomas Mitt , Jacques Y. Roberge , James R. Corte , Steven H. Spergel , Richard A. Rampulla , Raj N. Misra , Hai-Yun Xiao

IPC分类号： A61K31/44 , A61K31/40 , C07D491/00 , C07D487/00

CPC分类号： C07D487/18 , A61K31/00 , A61K31/403 , A61K31/407 , A61K31/655 , A61K31/675 , A61K45/06 , C07B2200/11 , C07D401/08 , C07D471/08 , C07D487/08 , C07D491/08 , C07D491/18 , C07D491/22 , C07D495/08 , C07D495/18 , C07D519/00 , C40B40/00 , A61K2300/00

摘要： Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

3.

发明授权
Fused cyclic modulators of nuclear hormone receptor function 有权

公开(公告)号：US07432267B2

公开(公告)日：2008-10-07

申请号：US11168223

申请日：2005-06-28

申请人： Mark E. Salvati , James Aaron Balog , Weifang Shan , Sören Giese , Lalgudi S. Harikrishnan

发明人： Mark E. Salvati , James Aaron Balog , Weifang Shan , Sören Giese , Lalgudi S. Harikrishnan

IPC分类号： C07D487/08 , A61K31/498

CPC分类号： C07D487/08 , A61K31/00 , A61K31/407 , A61K31/655 , A61K31/675 , C07D487/14 , A61K2300/00

摘要： Disclosed are compounds having the formula (I): including compounds of formulae (Ia) and (Ib): wherein G is an optionally substituted aryl or heterocyclo, L is an optional linker, M is a bond, O, CR7R7′ or NR10, and M′ is a bond or NR10, with the proviso that at least one of M or M′ must be a bond; E is C=Z2, CR7CR7′, SO2, P═OR2, or P═OOR2; Z1 is O, S, NH, or NR6; A1 is CR7 or N; A2 is CR7 or N; Y is J-J′-J″ where J is (CR7R7′)n and n=0−3, J′ is a bond or O, S, S═O, SO2, NH, NR6, C═O, CO═O, NR1C═O, CR7R7′, C═CR8R8′, R2P═O, OPOOR2, OPO2, OSO2, C═N, NHNH, NHNR6, NR6NH, N═N, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo or aryl or substituted aryl, and J″ is (CR7R7′)n and n=0−3; and W, Q, R2, R6, R7, R7′, R8, R8′, R9, R9′, and R10 are as defined in the specification and/or claims herein, to methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and to pharmaceutical compositions containing such compounds.